Neuroprotective Strategies in Preclinical Animal Models of Neurological Disorders

Dear Colleagues,

understanding neuroprotective mechanisms is crucial for tackling the onset and progression of neurological disorders, including a broad spectrum of neurodegenerative and neurodevelopmental diseases. Preclinical animal models are essential tools for dissecting the molecular and cellular events underlying neuronal injury, synaptic dysfunction, neuroinflammation, glial alterations, and retinal–brain degeneration. These models provide unique platforms for investigating intracellular signaling pathways, microglia–neuron interactions, oxidative stress responses, and the contribution of protein post-translational modifications to neuronal vulnerability. They also support the development and validation of innovative therapeutic strategies, including peptide-based inhibitors, neurotrophins, antioxidants, gene-targeted interventions, and small-molecule modulators aimed at preventing neuronal loss and restoring synaptic function. We are pleased to invite you to submit your latest findings to this Special Issue.

This Special Issue aims to highlight advances in experimental neuroprotection using preclinical animal models, with a focus on molecular and cellular pathways that promote neuronal resilience and early therapeutic intervention. The topic aligns with the journal’s mission to publish biologically relevant studies that contribute to understanding human nervous system health and disease. This collection seeks to bridge mechanistic discoveries with translational potential, fostering interdisciplinary perspectives for the prevention and treatment of neurological disorders.

In this Special Issue, original research articles and review papers are welcome. Potential topics include, but are not limited to, the following:

• Neuroprotective mechanisms in neurodegeneration and neurodevelopmental disorders;
• Synaptic protection and restoration of neuronal connectivity;
• Microglia–neuron interaction and glial-mediated neuroprotection;
• Intracellular signaling pathways and protein post-translational modifications;
• Antioxidants, neurotrophins, peptide-based or gene-targeted therapies;
• Biomarkers of neuroprotection and early therapeutic intervention;
• Retina–brain axis and visual system models in neuroprotection.

We look forward to receiving your contributions.

Dr. Lucia Buccarello
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.